• +1-646-491-9876
    • +91-20-67278686

    Search

    Nocturia - Pipeline Review, H1 2017

    Nocturia - Pipeline Review, H1 2017

    • Report Code ID: RW0001689418
    • Category Healthcare
    • No. of Pages 33
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Pipeline Review, H1 2017, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape.

    Nocturia is defined as need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women, sometimes for different reasons. Causes of nocturia include congestive heart failure, edema of lower extremities, sleeping disorders such as obstructive sleep apnea, certain drugs, including diuretics (water pills), cardiac glycosides, demeclocycline, lithium, methoxyflurane, phenytoin, propoxyphene, and excessive vitamin d and drinking too much fluid before bedtime, especially coffee, caffeinated beverages, or alcohol. Treatment includes anticholinergic medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Nocturia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Nocturia (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 2 and 2 respectively.

    Nocturia (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System And Sex Hormones).
    - The pipeline guide reviews pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Nocturia (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Nocturia (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Nocturia - Overview
    Nocturia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Nocturia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Nocturia - Companies Involved in Therapeutics Development
    Allergan Plc
    Astellas Pharma Inc
    Ferring International Center SA
    Sanwa Kagaku Kenkyusho Co Ltd
    Vantia Therapeutics
    Nocturia - Drug Profiles
    (acetaminophen + ibuprofen) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-7035 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-7398 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    desmopressin acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    desmopressin acetate ODT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fedovapagon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SK-1404 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nocturia - Dormant Projects
    Nocturia - Product Development Milestones
    Featured News & Press Releases
    Oct 20, 2016: FDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray)
    May 08, 2016: Studies Demonstrate New Options to Help Prevent and Treat Nocturia
    May 03, 2016: Allergan Presents New Data on SER120 at the American Urological Association Meeting in San Diego
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Nocturia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Nocturia - Pipeline by Allergan Plc, H1 2017
    Nocturia - Pipeline by Astellas Pharma Inc, H1 2017
    Nocturia - Pipeline by Ferring International Center SA, H1 2017
    Nocturia - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017
    Nocturia - Pipeline by Vantia Therapeutics, H1 2017
    Nocturia - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Nocturia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Astellas Pharma Inc
    Ferring International Center SA
    Sanwa Kagaku Kenkyusho Co Ltd
    Vantia Therapeutics

    Request for Sample

    Report Url http://www.reportsweb.com//nocturia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//nocturia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//nocturia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments